Janux Therapeutics Quarterly Balance Sheet
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Janux Therapeutics financial position
As of Jun 30, 2026, Janux Therapeutics reported total assets of $1.01 billion, down 2.4% from a year earlier against total liabilities of $79.7 million. Shareholders' equity stood at $928.0 million, or 92.1% of assets. The company held $27.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.35, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Janux Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 27.77M | 51.83M | 52.33M | 48.39M | 52.45M | 73.74M | 430.61M | 26.75M | 14.66M | 212.80M | 19.20M | 17.15M |
| Short-Term Investments | 943.14M | 904.56M | 914.23M | 940.60M | 943.57M | 940.40M | 594.57M | 631.28M | 631.63M | 438.96M | 324.82M | 332.56M |
| Receivables | 149.00K | 35.00M | 0 | — | — | — | — | — | 7.50M | 519.00K | 0 | 0 |
| Total Current Assets | 983.34M | 1.00B | 975.89M | 998.09M | 1.01B | 1.02B | 1.03B | 666.32M | 661.94M | 658.67M | 349.24M | 355.19M |
| Property, Plant & Equipment | 3.26M | 3.55M | 3.85M | 4.31M | 4.69M | 4.95M | 4.86M | 5.37M | 5.94M | 6.52M | 7.00M | 7.32M |
| Total Assets | 1.01B | 1.03B | 1.00B | 1.02B | 1.03B | 1.05B | 1.06B | 695.02M | 691.41M | 688.98M | 380.41M | 386.85M |
| Accounts Payable | 3.02M | 3.38M | 4.97M | 3.40M | 3.48M | 2.35M | 4.03M | 2.46M | 1.25M | 2.25M | 2.42M | 2.50M |
| Total Current Liabilities | 60.15M | 58.91M | 25.00M | 27.83M | 21.38M | 17.50M | 17.46M | 17.17M | 11.54M | 10.61M | 13.03M | 14.47M |
| Total Liabilities | 79.67M | 86.69M | 44.74M | 48.21M | 41.70M | 38.30M | 38.73M | 38.91M | 33.73M | 33.22M | 36.06M | 37.90M |
| Shareholders' Equity | 927.98M | 941.53M | 956.82M | 976.55M | 990.52M | 1.01B | 1.02B | 656.10M | 657.68M | 655.76M | 344.35M | 348.95M |
| Retained Earnings | -397.71M | -375.74M | -351.38M | -319.44M | -295.12M | -261.26M | -237.76M | -217.54M | -189.48M | -183.52M | -168.76M | -157.00M |
| Net Cash (Debt) | 970.91M | 956.39M | 966.57M | 988.99M | 996.01M | 1.01B | 1.03B | 658.03M | 646.29M | 651.76M | 344.03M | 349.71M |
| Shares Outstanding | 61.08M | 60.87M | 60.38M | 60.12M | 59.30M | 59.17M | 59.06M | 52.34M | 52.16M | 51.84M | 46.25M | 46.15M |
This table shows 12 quarterly periods of Janux Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow JANX's reporting calendar. What is a balance sheet?